TY - JOUR
T1 - Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism
AU - Liu, Ming Che
AU - Chiang, Han-Sun
AU - Chen, Kuan-Chou
AU - Hsieh, K.J.
PY - 2004
Y1 - 2004
N2 - Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.Periodic examinations were made of the prostate size, PSA (prostate specific antigen), anduroflow, as well as a follow up questionnaires with subjective screening of the voidingfunction, sexual function, and male climacteric symptoms were given. Results: Neither theprostate size nor serum PSA level of any patient were altered. For patients withhypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2months of isoflavone treatment (with an increase in the average peak flow rate of from 6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, generalweakness, and skin atrophy were found to have diminished by scoring in the group ofdiseased patients. As a natural product, isoflavone was quite acceptable to these middleaged to elderly patients, and no adverse effects were recorded. Conclusion: Althoughneither all of the patients nor all of the symptoms were responsive to 2 months of treatmentwith this medication in our series, isoflavone did, however, truly benefit some patients withclimacteric symptoms and/or prostatism and may be an alternative therapy for aging males.
AB - Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.Periodic examinations were made of the prostate size, PSA (prostate specific antigen), anduroflow, as well as a follow up questionnaires with subjective screening of the voidingfunction, sexual function, and male climacteric symptoms were given. Results: Neither theprostate size nor serum PSA level of any patient were altered. For patients withhypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2months of isoflavone treatment (with an increase in the average peak flow rate of from 6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, generalweakness, and skin atrophy were found to have diminished by scoring in the group ofdiseased patients. As a natural product, isoflavone was quite acceptable to these middleaged to elderly patients, and no adverse effects were recorded. Conclusion: Althoughneither all of the patients nor all of the symptoms were responsive to 2 months of treatmentwith this medication in our series, isoflavone did, however, truly benefit some patients withclimacteric symptoms and/or prostatism and may be an alternative therapy for aging males.
KW - isoflavone
KW - climacterics symptoms
KW - prostatism
KW - aging male
KW - 男性更年期
KW - 攝護腺肥大症狀
KW - 男性老化
M3 - Article
SP - 249
EP - 256
JO - Fu-Jen Journal of Medicine
JF - Fu-Jen Journal of Medicine
ER -